

1 **Title: Sex-specific genetic loci linked to early and late onset type 2 diabetes**

2 **Short title:** Sex-specific genetic loci in T2D

3

4 Jaime Berumen<sup>1\*</sup>, Lorena Orozco<sup>2</sup>, Héctor Gallardo-Rincón<sup>3,4\*</sup>, Rosa Elba Benuto<sup>5</sup>,  
5 Espiridión Ramos-Martínez<sup>1</sup>, Fernando Rivas<sup>1</sup>, Humberto García-Ortiz<sup>2</sup>, Melissa Marin-  
6 Medina<sup>5</sup>, Elizabeth Barrera<sup>1</sup>, Eligia Juárez-Torres<sup>5</sup>, Anabel Alvarado Silva<sup>5</sup>, Luis Alberto  
7 Martínez-Juárez<sup>4</sup>, Julieta Lomelín-Gascón<sup>4</sup>, Alejandra Montoya<sup>4</sup>, Janinne Ortega-Montiel<sup>4</sup>,  
8 Diego-Abelardo Alvarez-Hernández<sup>4</sup>, Roberto Tapia-Conyer<sup>6</sup>

9

10 1. Unidad de Investigación en Medicina Experimental, Facultad de Medicina, Universidad  
11 Nacional Autónoma de México, Ciudad de México, México.

12 2. Instituto Nacional de Medicina Genómica, Ciudad de México, México.

13 3. Universidad of Guadalajara, Health Sciences University Center, Guadalajara, Jalisco,  
14 México

15 4. Fundación Carlos Slim, Ciudad de México, México.

16 5. Laboratorio HuellaGénica, Ciudad de México, México.

17 6. Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México,  
18 México

19

20 **\*Corresponding authors:**

21 Jaime Berumen

22 Unidad de Investigación en Medicina Experimental, Hospital General de México. Dr. Balmis  
23 148, Doctores, Cuauhtémoc, 06720 Ciudad de México, CDMX, México

24 Phone: 52 55 1850 4023

25 Email: [jaimeberumen47@gmail.com](mailto:jaimeberumen47@gmail.com)

26 Héctor Gallardo-Rincón

27 Fundación Carlos Slim

28 Lago Zurich 245, Presa Falcon Building (Floor 20), Col. Ampliacion Granada, Miguel

29 Hidalgo, 11529, México City, México

30 Phone: +52 55 4976 0344

31 Email: [hgallardo@fundacioncarlosslim.org](mailto:hgallardo@fundacioncarlosslim.org)

32

33 **Support for paper writing:**

34 Writing support was funded by the Fundación Carlos Slim.

35

36 **Disclosure statement:**

37 H.G.R., L.A.M.J., J.L.G., A.M., J.O.M., and D.A.A.H. are employed by the

38 Fundación Carlos Slim. All other authors have nothing to disclose.

39

40 **Word count, abstract:** 259

41 **Word count, text:** 5358

42 **Number of tables/figures:** 2/6

43 **Supplementary materials:** 14 tables

44 **Abstract**

45 **Purpose**

46 To investigate the effect of sex and age on the timing of a type 2 diabetes (T2D) diagnosis  
47 and the influence T2D-related genes, parental history of T2D, and obesity on T2D  
48 development.

49 **Methods**

50 In this case-control study, 1012 T2D cases and 1008 healthy subjects were selected from  
51 the Diabetes in Mexico Study database. Participants were stratified by sex and age at T2D  
52 diagnosis (early,  $\leq 45$  years; late,  $\geq 46$  years). Seventy T2D-associated SNPs were explored  
53 and the percentage contribution ( $R^2$ ) of T2D-related genes, parental history of T2D, and  
54 obesity (body mass index [BMI] and waist-hip ratio [WHR]) on T2D development was  
55 calculated using univariate and multivariate logistic regression models.

56 **Results**

57 T2D-related genes influenced T2D development most in males who were diagnosed early  
58 ( $R^2 = 23.5\%$ ; females diagnosed early,  $R^2 = 13.5\%$ ; males and females diagnosed late,  $R^2 =$   
59  $11.9\%$  and  $R^2 = 7.3\%$ , respectively). With an early diagnosis, insulin production genes were  
60 more influential in males (76.0% of  $R^2$ ) whilst peripheral insulin resistance genes were more  
61 influential in females (52.3% of  $R^2$ ). With a late diagnosis, insulin production genes from  
62 chromosome region 11p15.5 notably influenced males while peripheral insulin resistance  
63 and inflammation genes notably influenced females. Influence of parental history was higher  
64 among those diagnosed early (males, 19.9%; females, 17.5%) versus late (males, 6.4%;  
65 females, 5.3%). Unilateral maternal T2D history was more influential than paternal T2D  
66 history. BMI influenced T2D development for all, while WHR exclusively influenced males.

67 **Conclusions**

68 The influence of T2D-related genes, maternal T2D history, and fat distribution on T2D  
69 development was greater in males than females.

70 **Keywords:** age, genetic loci, obesity, sex, type 2 diabetes, parental history

71 **Introduction**

72 The etiological parameters of type 2 diabetes (T2D) have not been fully elucidated; however,  
73 T2D is clearly associated with obesity, parental history, genes, ethnicity, poor eating habits,  
74 dyslipidemia, lack of physical activity, and aging, among others (1). Of these, obesity,  
75 parental history, and genes appear most important. Obesity, a modifiable factor, is clearly  
76 associated with T2D development and is considered the main risk factor; T2D risk increases  
77 linearly with increased body mass index (BMI) (2-4). However, the relationship between T2D  
78 and obesity may not be as direct as thought. For example, in countries such as China, India,  
79 and Japan, where the prevalence of T2D is high, the prevalence of obesity is relatively low.  
80 Currently, we know that approximately two-thirds of people with T2D are overweight or  
81 obese; however, only 2%–13% of obese people develop T2D. When using univariate logistic  
82 regression (ULR) models, we recently reported that the variability ( $R^2$ ) of T2D attributed to  
83 obesity would be 12.6%–14.9% (5). However, these values vary substantially in multivariate  
84 logistic regression (MLR) models that include parental history of T2D and genes as variables  
85 (5).

86 The importance of parental history on T2D development has been well established in  
87 both family (6-8) and association studies (9). The heritability of T2D is variable, reported to  
88 be around 25% in family studies (9-11) and 20% in association studies (6, 7, 12). In a case–  
89 control study conducted in Mexico, the  $R^2$  of T2D attributed to parental history of diabetes  
90 was 12.1%. There are currently over 400 genes with an identified association with T2D (13).  
91 However, based on their low individual odds ratios (OR), most genes have very little  
92 influence on the development of the disease, which can vary with different study populations.  
93 Most studies suggest that genetic involvement contributes to no more than 10% of T2D  
94 variability (13, 14). Recently, a study of 16 single nucleotide polymorphisms (SNPs) with the  
95 highest predictive power for T2D in a Latin American population reported that only nine were  
96 associated with T2D and that this contributed to only 6.5% of T2D variability (5). However,  
97 as previously reported (15), this study found that parental history and genes have a greater  
98 influence on T2D when it occurs before the age of 46 and that the influence of these factors

99 decreases substantially when the disease is diagnosed later in life ( $\geq 46$  years). Furthermore,  
100 this study also found an important difference in the association of genes, but not of parental  
101 history, with T2D between males and females (15). Here, the  $R^2$  value was much higher in  
102 males than females (11.2% versus 4.1%), and given that the differences in gene association  
103 between males and females have not been previously reported or have only been reported  
104 for individual genes (16, 17), the differences are likely specific to the ancestry of populations  
105 in Mexico, which include a mixture of different Amerindian and European ancestries.

106 In fact, in recent high-throughput studies, as part of the Slim Initiative in Genomic  
107 Medicine for the Americas (SIGMA), polymorphisms strongly associated with T2D have been  
108 discovered in Mexican and Latin populations that are either non-existent or very rare in  
109 European populations. These polymorphisms are located in *SLC16A11* (18), *INS-IGF2* (19),  
110 and *HNF1A* (20). Here, the difference between the  $R^2$  values of males and females may be  
111 partially explained by the difference in the effect size of these genes between sexes. We  
112 note that polymorphisms in well-established genes associated with T2D in multiple  
113 populations, such as *KCNQ1* and *TCF7L2*, are also important contributors to this difference  
114 (5). Because of the small number of genes analyzed in a previous study, we were unable to  
115 investigate which biological processes associated with T2D (e.g., insulin production,  
116 peripheral insulin resistance, inflammation) were most relevant for the genetic differences  
117 between men and women and between early- and late-onset T2D. Given the difference in  
118 the degree of association of genes between the two sexes and between the late and early  
119 presentation of T2D, it is likely that the biological processes associated with T2D in each  
120 group are markedly different.

121 In this work, a case-control study ( $n = 2020$ ) was performed, including 69 SNPs  
122 associated with T2D located in genes involved in different biological processes. The aim was  
123 to solve the following research questions: 1) to confirm whether the influence of genes on  
124 T2D is different between men and women, 2) to investigate which biological processes have  
125 different weights of contribution in T2D between sexes and age at T2D presentation, and 3)  
126 to understand how the contribution of each biological process changes in each group when

127 obesity and parental history of diabetes are included in the MLR models. To identify the  
128 factors associated with T2D in each group, univariate logistic regression (ULR) models were  
129 used. Then, MLR models were used to calculate the percentage contribution ( $R^2$ ) of each  
130 factor to the variability of T2D. In the latter, the genes (grouped by biological processes) and  
131 the remaining factors were entered in successive blocks to calculate the contribution of each  
132 factor ( $R^2$ ) in the global model. The variation in the order of entry of each factor allowed us to  
133 identify how obesity and parental history affect the importance of gene biological processes  
134 linked to insulin production and resistance in the variability of T2D between sexes and age of  
135 disease onset.

136

## 137 **Material and Methods**

### 138 ***Sample selection and study design***

139 Study participants were part of the Diabetes in Mexico Study (DMS) (21). The DMS study  
140 design was previously described as part of the SIGMA Type 2 Diabetes Consortium. Briefly,  
141 participants were recruited from two tertiary-level hospitals in Mexico City (Centro Médico  
142 Nacional siglo XXI del Seguro Social Mexicano [IMSS], Centro Médico Nacional 20 de  
143 Noviembre del Seguro Social para los Trabajadores del Estado [ISSSTE]). T2D was  
144 diagnosed according to the criteria of the American Diabetes Association (22). A total of  
145 1012 cases (unrelated individuals, >20 years old, with a previous diagnosis of T2D or fasting  
146 glucose levels >125 mg/dL) and 1008 controls (healthy subjects, >50 years old, fasting  
147 glucose levels <100 mg/dL) were selected from the DMS database, which consisted of 1500  
148 controls and 1500 cases of the Latin American mestizo population. Participants and same-  
149 sex, same-hospital controls were recruited between November 2009 and August 2013.  
150 Clinical information including weight, waist and hip circumference, and parental history of  
151 T2D was collected during the initial interview. For fasting glucose measurements and DNA  
152 extraction, 10 mL of intravenous blood was collected. The association of the 69 selected  
153 SNPs, parental history of T2D, BMI, and WHR with T2D was investigated using ULR and  
154 MLR models.

155 This study was approved by the Ethics and Research Committees of the National  
156 Institute of Genomic Medicine and the Federal Commission for the Protection against Health  
157 Risks (COFEPRIS; approval number CAS/OR/CMN/113300410D0027-0577/2012). The  
158 study protocols were carried out in accordance with the ethical principles outlined in the  
159 1964 Declaration of Helsinki. Written informed consent was obtained from all participants  
160 prior to their inclusion in the study. This study was not registered in a clinical trial registry.

161

### 162 ***SNP selection and genotyping***

163 Sixty-nine SNPs were selected; nine associated with T2D in a previous study (5) and 60  
164 from different GWAS databases and published articles (**Table S1**). SNPs with a minor allele  
165 frequency (MAF)  $\geq 10\%$  and OR  $\geq 1.2$  or  $\leq 0.83$  in the Latin American mestizo population and  
166 those localized in genes with a role in cellular processes involved in T2D development were  
167 prioritized. All DNA samples were genotyped for the 69 SNPs listed in **Table S1**. Assays  
168 were designed using Applied Biosystems TaqMan SNP assay design technology (Foster  
169 City, CA, USA). Genotyping was performed by the allelic discrimination assay-by-design  
170 TaqMan® method on OpenArray® plates. The plates were analyzed on the QuantStudio™  
171 12 K Flex Real-Time PCR System (ThermoFisher Scientific, Waltham, MA, USA). The  
172 genotypes were analyzed by Genotyper™ Software v1.3 (ThermoFisher Scientific, Waltham,  
173 MA, USA).

174 A total of 23 SNPs that had a difference of distribution between cases and controls of  
175  $P < 0.2$  in the ULR models were ultimately included in the MLR models. The list of SNPs and  
176 gene symbols are presented in **Table 1**, and the names of genes and their function in **Table**  
177 **S2**. The SNPs were classified into four groups according to the function and location of the  
178 gene in which they occur: Group 1, insulin production located in chromosome region  
179 11p15.5 (n = 5); Group 2, insulin production located in other regions (n = 7); Group 3,  
180 peripheral insulin resistance (n = 6); and Group 4, inflammation and other functions (n = 5)  
181 (**Table 1, Table S2**).

182

### 183 **Statistical analyses**

184           When determining the sample size, we considered MLR models to have good  
185 performance when there was a baseline of 50 cases (as in the ULR models) and 10–15  
186 additional cases for each variable introduced in the model (23). Given that we planned to  
187 introduce 15–20 variables in the MLR models, we calculated a minimum number of 200–350  
188 cases in the comparison groups.

189           Participant age, age at T2D diagnosis, BMI, and WHR were expressed as mean ±  
190 standard deviation (SD). Distribution of the frequency of genotypes according to the Hardy–  
191 Weinberg law based on the allelic frequency and the formula:  $(a + b)^2 = a^2 + 2ab + b^2$ , where  
192  $a$  and  $b$  are the allelic frequencies in the control group, was investigated. Differences in the  
193 distribution of genotypes between the observed and expected results were calculated using  
194 the chi-square test. The BMI was adjusted (BMIadj) for participants who had been diagnosed  
195 with T2D for ≥3 years using data from patients who had been diagnosed with T2D for ≤2  
196 years (5). In the ULR and MLR models, case (diagnosis of T2D) or control was considered a  
197 dependent variable; values of the alleles and genotypes of the SNPs, parental history, BMI,  
198 and WHR were considered explanatory variables. Interactions between each SNP and both  
199 sex and age of T2D presentation were assessed in the ULR models. All variables (BMIadj,  
200 WHR, parental history of T2D, and SNPs) were analyzed with stratification by sex (male and  
201 female) and age at T2D diagnosis (≤45 years and ≥46 years). The risk conferred by each  
202 factor (explanatory variables) was calculated by comparing cases and controls using ULR  
203 models. Association was expressed as an OR with 95% confidence intervals (CIs); the  
204 contribution to the variability of T2D was expressed as Nagelkerke's  $R^2$ , which represents  
205 the percentage of T2D variability that can be explained by a named factor (24). Confounders  
206 were identified using a theoretical strategy based on a backstep, stepwise MLR model and  
207 the change-in-estimate criterion. Variables with  $P < 0.20$  in the ULR analysis were  
208 considered for entry in the MLR model. Confounders were defined as those variables for  
209 which the percentage difference between the values of the regression  $\beta$  between the



210 adjusted and non-adjusted variables in the stepwise MLR model was larger than 10% ( $P >$   
211 0.1). Therefore, the total variability and the contribution of each factor on T2D was calculated  
212 using this MLR model. These factors were included successively in the model in different  
213 blocks, and the contribution of each factor to the model was assessed by the increase of  $R^2$   
214 and the decrease in the  $-2 \log$  likelihood ratio value from one block to the next; the Omnibus  
215 test was used to determine whether the differences between the successive blocks were  
216 statistically significant. A post-hoc power analysis was performed for each logistic regression  
217 model using the software G \* Power 3.1.9.2, considering the sample size, the OR, the  
218 probability of the event in the control group, and an  $\alpha = 0.05$  (25). In addition, for MLR  
219 models, the value of the total  $R^2$  obtained at the end of the model was introduced for power  
220 calculation.

221 All statistical tests were two-sided, and differences were considered significant when  
222  $P < 0.05$ . Statistical analyses were conducted using SPSS version 20 software (IBM Corp.,  
223 Armonk, NY, USA).

224 **Results**

225 ***Participant characteristics***

226 The 2020 participants (cases, 1012; controls, 1008) were included in the SNP and BMI  
227 analyses; given missing data for some participants, 1690 were included in the parental  
228 history analysis of T2D and 1335 in the WHR analysis. WHR was not included in some MLR  
229 models; a total of 1690 participants were included in models where parental history was  
230 introduced. The demographic characteristics of patients with T2D and non-diabetic controls  
231 are presented in **Table S3**.

232 Among the participants, 53.9% were female and 46.1% were male. The mean  $\pm$  SD  
233 age of non-diabetic controls ( $59.1 \pm 11.3$  years) was higher than that of cases ( $55.5 \pm 11.7$   
234 years) at the time of enrollment. The mean  $\pm$  SD age at T2D diagnosis was  $45.8 \pm 10.7$   
235 years, and the number of years with T2D varied widely (range, 0–46 years; mean  $\pm$  SD,  $9.5$   
236  $\pm 8.7$  years). At the time of study recruitment, most patients (89.5%) were taking medication  
237 for their T2D, and few were smokers (cases, 20.2%; controls, 19.8%).

238

239 ***Identification of genes associated with T2D using ULR models***

240 The allelic frequencies of only 23 (**Table 1**) of the 69 SNPs explored (**Table S1**) were  
241 significantly different ( $P < 0.1$ ) between cases and controls in all participants (**Table S4**),  
242 stratified by age at T2D diagnosis ( $\leq 45$  years and  $\geq 46$  years) (**Table S4**), sex (male and  
243 female) (**Table S5**), or both (**Table S6**).

244 In the allelic ULR analysis, 12 of 23 SNPs showed a significant association with T2D  
245 for the entire study population (**Table 1**). The  $R^2$  sum of these 12 SNPs only explains 5.3%  
246 of the variability of T2D etiology.

247 When analyzed according to age of T2D diagnosis ( $\leq 45$  years versus  $\geq 46$  years), 8  
248 of the 12 SNPs associated with T2D in the whole sample were associated with T2D in both  
249 age groups (**Table S7**). SNPs in *SLC30A8* (rs3802177), *NOS3* (rs2070744), and *KHDRBS3*  
250 (rs6577691) were associated only with early T2D diagnosis and SNPs in *CACNA1H*  
251 (rs4984636) were only associated with late diagnosis. Two additional SNPs, not associated

252 with T2D in the analysis of the entire study population, were also identified: *WFS1*  
253 (rs4458523) (associated with early T2D diagnosis) and *HMG20A* (rs1005752) (associated  
254 with late T2D diagnosis) (**Table S7**). No major differences were observed in the association  
255 of gene groups between early or late T2D diagnosis. However, all SNPs except *INS-IGF2*  
256 (rs149483638) had a greater association with early than late T2D diagnosis. Compared with  
257 the overall analysis, the  $R^2$  sum increased in SNPs associated with early T2D diagnosis ( $R^2$   
258 sum = 7.37%) and decreased in those associated with late T2D diagnosis ( $R^2$  sum = 3.32%).

259 There was a significant interaction ( $P < 0.1$ ) between sex and some SNPs, both in  
260 the entire study population ( $n = 8$ ) and when stratified by early ( $n = 9$ ) and late ( $n = 6$ ) T2D  
261 diagnosis (**Table 1, Table S7**). **Table S5** shows allelic frequency and **Table S7** shows the  
262 ULR results stratified by sex. Twelve and eight of 23 SNPs were associated with T2D  
263 exclusively in males and females, respectively; five were associated with both sexes. A large  
264 difference was observed in the association of different groups of genes between males and  
265 females. For example, all five SNPs on the chromosome region 11p15.5 were associated  
266 with T2D in males but only three SNPs were in females. The two SNPs that were not  
267 associated with T2D in females were located at the upstream end of the region where *INS*  
268 and *IGF2* are located. Those shared with males, however, were located in the downstream  
269 region (*KCNQ1* and *SLC22A18*) (**Figure 1**). The two SNPs located in *KCNQ1* had a stronger  
270 association with T2D in males than females (OR  $>1.6$  versus OR = 1.2;  $P < 0.0001$  versus  $P$   
271  $< 0.05$ ), while the SNP in *SLC22A18* had a slightly higher association in females versus  
272 males (OR  $>1.43$  versus OR = 1.32;  $P < 0.0002$  versus  $P < 0.007$ ). None of the seven SNPs  
273 in genes involved with insulin production located in other genomic regions (Group 2) were  
274 associated with T2D in females; however, three SNPs (*IGF2BP2* [rs4402960], *TCF7L2*  
275 [rs7903146], *SLC30A8* [rs3802177]) were associated in males. Peripheral resistance  
276 appears more important than insulin production for T2D development in females. The SNP in  
277 *SLC16A11* had a greater effect in females than males (OR  $>1.37$  versus OR = 1.24;  $P <$   
278  $0.0004$  versus  $P < 0.021$ ) and the SNP in *PPP1R3A* was only associated with T2D in  
279 females.

280 Overall, ORs were higher and  $P$  values lower in genes associated with T2D in males  
281 versus females. In females, the highest ORs were reported for SNPs in *SLC16A11* (OR,  
282 1.37) and *SLC22A18* (OR, 1.43), while there were five SNPs with an OR > 1.5 (located in  
283 *IGF2BP2*, *INS*, *KCNQ1*, and *TCF7L2*) for males. The  $R^2$  sum was 3.5% for females and  
284 10.7% for males. When the analysis was stratified by sex and age of T2D detection some  
285 differences in the associations of groups of genes were seen between the two groups of  
286 males and females (**Table 2** and see below in the MLR analysis).

287 The observed genotypic frequency was distributed according to the Hardy–Weinberg  
288 law in all 23 SNPs studied (**Table S8**). Genotypic frequency is shown in **Table S9** (the total  
289 sample stratified by age at T2D diagnosis), **Table S10** (stratified by sex), and **Table S11**  
290 (stratified by age at T2D diagnosis and sex). Overall, SNPs associated with T2D in the allelic  
291 ULR analysis also showed a significant association in the ULR genotype analysis (**Table**  
292 **S12**). However, in all ULR genotypic models,  $R^2$  sum values were much higher than those  
293 observed in the univariate allelic models, clearly indicating that genotypes rather than alleles  
294 should be used in MLR models.

295

### 296 ***Degree of participation of each group of genes in the variability of T2D using MLR*** 297 ***models***

298 The MLR analyses were performed with the SNP groups (Group 1, Group 2, Group 3, and  
299 Group 4) introduced in successive blocks. Most SNPs identified by ULR, except the SNP  
300 rs450208 (*SLC22A18*) in males and SNP rs2237897 (*KCNQ1*) in females, which could be in  
301 partial linkage disequilibrium with some of the other three SNPs located in chromosome  
302 region 11p15.5 (**Table S13**), remained in the MLR models (**Table S14**).

303 The influence of genes on T2D was greatest in males diagnosed early (23.5%),  
304 followed by females diagnosed early (13.5%), males diagnosed late (11.9%), and females  
305 diagnosed late (7.3%). Genes on the chromosome region 11p15.5 (40.3% of the  $R^2$ ; **Figure**  
306 **2A**) and others involved in insulin production (35.7% of the  $R^2$ ; **Figure 2A**) had the greatest  
307 effect in males diagnosed early, which contrasts with the major influence of genes involved

308 in peripheral insulin resistance in females diagnosed early (52.3% of the  $R^2$ ; **Figure 2A**).  
309 Also notable, males diagnosed late had a predominance of associated SNPs in genes of the  
310 chromosome 11p15.5 region, which contrasts with the lower  $R^2$  values of the same SNPs in  
311 females diagnosed late. Although an increase in the influence of genes involved with  
312 inflammation was observed in males and females diagnosed late, it accounted for nearly one  
313 quarter of the genes' influence in females.

314

### 315 ***Influence of parental history of T2D***

316 Parental history had the strongest influence in those cases diagnosed with T2D at  $\leq 45$  years  
317 of age (males, 19.9%; females, 17.5%) and the least influence in those cases diagnosed  
318 with T2D later in life ( $\leq 6.4\%$ ) (**Figure 2B**). History of T2D in both parents had the most  
319 influence in both males and females diagnosed early. In contrast, having only a father with  
320 T2D had little or no influence on T2D development whereas having a mother with T2D  
321 influenced T2D diagnosis, especially among males diagnosed early (25%) and females  
322 diagnosed late (50%). The risk of developing T2D early was approximately 10 times higher  
323 when both parents and three times higher when one parent had a history of T2D versus  
324 neither. In contrast, a history of T2D in both parents conferred a lower risk of T2D in those  
325 diagnosed late compared with an early diagnosis (males, 3.6 times higher; females, 2.7  
326 times higher versus neither parent with T2D) (data not shown).

327 In the four groups, the total value of  $R^2$  was higher when parental history was the first  
328 block and genes was the second block, particularly for males diagnosed early ( $R^2$ , 0.403)  
329 (**Figure 2C**). In this group, gene effects decreased from 0.251 to 0.201 (**Figure 2C**) as  
330 compared with genes in the first block. In contrast, the effect of parental history decreased  
331 when analyzing in the opposite order ( $R^2$  decreased from 0.202 to 0.119), suggesting a  
332 common effect on 5%–8% of T2D variance linked to genes and parental history of T2D, and  
333 that much of the effect of parental history is not directly due to the assessed genetic  
334 polymorphisms. Interestingly, when the effect of genes is reduced, there is not a uniform  
335 reduction for the four groups of genes. Rather, the influence ( $R^2$ ) of genes related to insulin

336 production is decreased (chromosome region 11p15.5 [Group 1], 32%; other genomic  
337 regions [Group 2], 34%) and in genes related to peripheral insulin resistance (Group 3), the  
338 influence is increased by 25%. In the reverse model (first block, genes; second block,  
339 parental history) the decreased influence of parental history was not uniform for a history in  
340 the father (decreased from a small effect to no effect), mother (60% decrease), or both (32%  
341 decrease) in males diagnosed early (**Figure 2C**). These data may suggest a relationship  
342 between SNPs on genes in the chromosome region 11p15.5 and a maternal history of T2D,  
343 especially given that genes in this region have genetic imprinting on the maternal side (26).  
344 When stratified by the type of parental inheritance, the distribution of risk alleles compared  
345 with alternative alleles for several 11p15.5 genes and *TCF7L2* only differs between cases  
346 and controls with unilateral maternal inheritance in males diagnosed early (**Figure 3**).

347

#### 348 ***Influence of obesity and fat distribution***

349 ULR revealed that BMI was important in all four groups of T2D (males diagnosed early,  $R^2 =$   
350 0.198; males diagnosed late,  $R^2 = 0.147$ ; females diagnosed early,  $R^2 = 0.132$ ; females  
351 diagnosed late,  $R^2 = 0.106$ ) (**Figure 4A**). WHR was most important for both male groups  
352 (**Figure 4A**). BMI results were similar in MLR models when BMI was the first block (**Figure**  
353 **5A** and **Figure 5B**). However, if BMI was the third block (following parental history and  
354 genetic influence), the effect decreases substantially (males diagnosed early, 54.6%; males  
355 diagnosed late, 34.3%; women diagnosed early, 40.7%; females diagnosed late, 19.9%)  
356 (**Figure 4B**).

357 Using MLR, the effects of genes and parental history were analyzed separately to  
358 determine how much each individually absorbs the effect of BMI (first block, genes or  
359 parental history, second block, BMI; first block, BMI, second block, genes or parental  
360 history). In males diagnosed early, parental history or genes decreased the effect of BMI by  
361 43.6% or 23.3%, respectively. With parental history as the first block, the effect was mainly  
362 absorbed by having a mother with T2D (87.2% increase) or both parents with T2D (72%  
363 increase); the effect of a father with T2D was minor (**Figure 5B**). With genes as the first

364 block, the effect of BMI was mainly absorbed by genes located in the chromosome region  
365 11p15.5 (58.5% increase) (**Figure 5A**). Similar increases with parental history or genes as  
366 the first block were observed in males diagnosed late and females diagnosed early (**Figure**  
367 **5A** and **Figure 5B**). A similar analysis was performed using WHR rather than BMI. The  
368 findings in males diagnosed early were similar to those found for BMI (**Figure 5C** and **Figure**  
369 **5D**) and together these results suggest that some components of parental history, and to a  
370 lesser extent genes on the chromosome 11p15.5 region, are linked to obesity.

371         Using the Pearson correlation, we found a positive correlation between the number of  
372 risk alleles in *KCNQ1* (chromosome 11p15.5 region) and both BMI and WHR in males  
373 diagnosed early ( $r = 0.125$ ,  $P = 0.001$  and  $r = 0.130$ ,  $P < 0.009$ , respectively) and late ( $r =$   
374  $0.103$ ,  $P < 0.007$  and  $r = 0.140$ ,  $P < 0.003$ , respectively) (**Figure 6**). A positive correlation  
375 was also observed between SNP in *INS* and BMI in males diagnosed early ( $r = 0.09$ ,  $P =$   
376  $0.019$ ; data not shown).

377         When BMI was introduced as the last block, the influence of BMI ( $R^2$ ) was similar  
378 among the four groups of T2D ( $R^2$  range: 0.078–0.094). However, the strength of the BMI  
379 effect related to parental history and genes appeared stronger for a late diagnosis compared  
380 with an early diagnosis (**Figure 4B**), indicating that obesity is more important than genetic  
381 influence and parental history for males and females diagnosed with late-onset T2D.

382 **Discussion**

383 This study identified notable differences in the association of T2D-related genes, parental  
384 history of T2D, BMI, and WHR with T2D development between males and females of Latin  
385 American mestizo origin. When participants were stratified by age of T2D presentation, the  
386 differences observed between males and females remained regardless of whether they were  
387 diagnosed with T2D early ( $\leq 45$  years) or late ( $\geq 46$  years). However, in males and females  
388 diagnosed late, the influence of genes and family history decreased drastically, while the  
389 influence of obesity increased. The reduced effect of T2D-related genes and parental history  
390 in late-onset T2D has previously been reported in other studies on White populations (27,  
391 28). The three factors (genetic loci, parental history, and BMI) appear related to each other,  
392 given that they each compete for a percentage of  $R^2$  (percent of T2D variability explained by  
393 each factor). In fact, the relationship of these three factors seems to be much more important  
394 in this studied population than in previously analyzed European populations (29).

395 The differences between males and females were most evident in those diagnosed with T2D  
396 early: 1) the genetic contribution involved in insulin production was predominant in males  
397 while genes involved in peripheral resistance were more important in females, 2) the  
398 influence of obesity, especially WHR, was much greater in males than females, and 3) the  
399 influence of a mother (unilateral) with a history of T2D greatly influenced males. Given genes  
400 that are involved in insulin production are located in autosomes, differences in T2D  
401 association should not be related to a differential distribution of risk alleles between males  
402 and females. Rather, this is most likely associated with external factors that differentially  
403 influence these genes in males and females. Our findings suggest that obesity, hormones,  
404 and maternal inheritance may be involved in the selection of males, but not females, who  
405 have risk alleles involved in insulin production for the early development of T2D. The  
406 association of BMI and especially WHR was much higher in males than females in the group  
407 that was diagnosed with T2D early (WHR 16x higher). Also, in males there was a linear  
408 correlation between BMI and WHR and the number of risk alleles in several genes located in  
409 the chromosome region 11p15.5 (*INS* and *KCNQ1*) that are associated with insulin



410 production. There is clear evidence that sex hormones play an important role in fat  
411 distribution, measured as WHR (30). WHR is a measurement of visceral fat (waist  
412 circumference) and gluteal fat (hip circumference). Gluteal-femoral fat predominates in  
413 females prior to menopause whereas abdominal fat predominates in postmenopausal  
414 females and males of all ages. Abdominal fat has been associated with an increased risk of  
415 developing T2D and cardiovascular disease (31). This may be contributing to the lower risks  
416 of developing T2D in premenopausal females compared with males of the same age (32).

417         The overall prevalence of T2D is slightly higher in males than females (33-35); in the  
418 2021 International Diabetes Federation report, the prevalence of T2D in males and females  
419 20–79 years of age was 10.8% and 10.2%, respectively (17.7 million more males than  
420 females with T2D). However, this difference is not uniform across age ranges; the difference  
421 is greatest among those  $\leq 55$  years of age (approximately 16.5% versus 13.5%) compared  
422 with those who are older, for whom the difference disappears with increasing age (17, 34-  
423 36). In Mexico, this difference appears even greater. For example, in 2019 the incidence of  
424 T2D was 17.2% higher in males than females aged 15–49 years (524 versus 447  
425 cases/100,000 persons) (37). This lower prevalence in younger females coincides with the  
426 premenopausal period, suggesting a protective effect for estrogens. This protective role has  
427 been demonstrated in studies of estradiol (38). Hormone replacement therapy is reported to  
428 reduce the incidence of T2D by 35% versus placebo in postmenopausal females (39) and  
429 early menopause is associated with an increased risk of T2D (40). Fasting glucose levels in  
430 premenopausal females are lower than those in age- and weight-matched males (41), while  
431 rat models have shown that estrogens protect against T2D by increasing insulin sensitivity  
432 (42, 43) and insulin secretion (43), and decreasing oxidative stress (42). This may suggest  
433 that a hormonal effect may protect or delay the impact of genes on the development of T2D  
434 in females. Furthermore, overweight or obese males may have low concentrations of serum  
435 testosterone, which is associated with an increased risk of T2D (44). A study of males aged  
436 50-74 years, with a waist circumference  $\geq 95$  cm, serum testosterone concentration  $\leq 14.0$   
437 nmol/L, and impaired glucose tolerance or newly diagnosed T2D investigated the effects of

438 participation in a lifestyle program with or without testosterone treatment on T2D (45). The  
439 study found that those who received testosterone treatment for 2 years had a greater  
440 reduction in 2-hour glucose versus baseline than those who received placebo (mean  
441 difference  $-0.75$  mmol/L;  $p < 0.0001$ ). Pancreatic islets have also been shown to be more  
442 susceptible to oxidative stress in males than females (46).

443 It has previously been shown that the influence of maternal history of diabetes is  
444 more important than paternal influence, at least for the early development of T2D (47). In the  
445 present study, we observed that the parental history of T2D through the mother (unilateral)  
446 may play an important role in differences in the association of risk alleles between the sexes  
447 in early-diagnosed T2D for two reasons: 1) MLR analysis revealed a substantial reduction in  
448 the influence of a mother with T2D when the groups of genes involved in insulin secretion  
449 were included in the first block and parental inheritance in the second, and 2) the distribution  
450 of risk alleles in *INS* and *KCNQ1* (chromosome 11p15.5 region) and *TCF7L2* was  
451 significantly different between cases and controls only when the mother had a history of T2D  
452 (not with the father or both parents). At least in the case of the chromosome 11p15.5 region,  
453 there is evidence of genetic imprinting on the maternal side; a previous study reported that  
454 risk alleles in *KCNQ1* conferred a risk for T2D only when are inherited by the mother (26)  
455 and that risk alleles influenced methylation levels of a regulatory sequence in fetal human  
456 pancreas, suggesting that diabetes risk effects may be mediated in early development (48).  
457 Interestingly, the effect of maternal inheritance on genes from that region was only observed  
458 in males with an early T2D diagnosis. Such an association has not been previously reported.

459 There were also important differences in the T2D models of males and females with  
460 a late T2D diagnosis. The effect size of T2D-related genes was larger in males than females,  
461 primarily at the expense of the genes involved with insulin production from the chromosome  
462 11p15.5 region. It is also noteworthy that in both groups with a late diagnosis, the proportion  
463 of the participation of genes involved with inflammation and other processes, relative to the  
464 total variance due to genes, was higher than in those with an early diagnosis. This could be  
465 related to increased inflammatory processes with aging (49).

466           This study had some limitations. As noted, the number of participants with missing  
467 data for WHR was notable. However, the important difference in the median WHR and the  
468 degree of association with T2D between men and women, as well as the significant  
469 correlation between WHR and the number of risk alleles of the *KCNQ1* gene, are very  
470 notable. These data could be considered valid because they were explored in ULR analyses.  
471 However, it is clear that the interpretation of the effect of WHR in MLR models should be  
472 confirmed in studies with a larger sample of cases and controls. Furthermore, this study is  
473 also limited by the inclusion of only Mexican participants and therefore the study findings are  
474 not necessarily generalizable to other populations.

475           The previous results allow us to conclude that the influence of T2D-related genes,  
476 maternal T2D history, and fat distribution on T2D development was greater in males than  
477 females.

478 **Funding**

479 This work was funded by the Fundación Carlos Slim, the Laboratory Huella Génica, and the  
480 Faculty of Medicine of the Universidad Nacional Autónoma de México (UNAM).

481

482 **Acknowledgements**

483 The authors thank Sarah Bubeck, PhD, of Edanz ([www.edanz.com](http://www.edanz.com)) for providing medical  
484 writing support, which was funded by Fundación Carlos Slim, in accordance with Good  
485 Publication Practice (GPP3) guidelines (<http://www.ismpp.org/gpp3>).

486

487 **Data Availability**

488 All data generated or analyzed during this study are included in this published article and its  
489 supplementary information files.

490

491 **Author contributions**

492 J.B. and R.T.C. made substantial contributions to the conceptualization of the study. J.B.,  
493 L.O., H.G.R., A.M., and R.T.C. contributed to the study methodology. F.R. utilized software.  
494 J.B. performed the formal analysis. H.G.O., M.M.M., E.B., E.J.T., A.A.S, L.A.M.J., and  
495 D.A.A.H. were involved in the study investigation. L.O., R.E.B., and H.G.O. provided  
496 resources for the study. J.B., H.G.R., L.A.M.J., A.M., D.A.A.H., and R.T.C were involved in  
497 visualization of the study data. J.B., H.G.R., and R.T.C. supervised the study. R.E.B. was  
498 involved in project administration and J.B. and R.T.C. acquired funding for the study. J.B.  
499 wrote the original draft and all authors reviewed and edited the manuscript.

500 **References**

- 501 1. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes  
502 mellitus and its complications. *Nat Rev Endocrinol*. 2018;14(2):88-98.
- 503 2. Carey VJ, Walters EE, Colditz GA, Solomon CG, Willett WC, Rosner BA, Speizer FE,  
504 Manson JE. Body fat distribution and risk of non-insulin-dependent diabetes mellitus  
505 in women. The Nurses' Health Study. *Am J Epidemiol*. 1997;145(7):614-619.
- 506 3. Hu FB. Obesity epidemiology. Oxford: Oxford University Press; 2008.
- 507 4. Zheng Y, Manson JE, Yuan C, Liang MH, Grodstein F, Stampfer MJ, Willett WC, Hu  
508 FB. Associations of weight gain from early to middle adulthood with major health  
509 outcomes later in life. *JAMA*. 2017;318(3):255-269.
- 510 5. Berumen J, Orozco L, Betancourt-Cravioto M, Gallardo H, Zulueta M, Mendizabal L,  
511 Simon L, Benuto RE, Ramírez-Campos E, Marin M, Juárez E, García-Ortiz H,  
512 Martínez-Hernández A, Venegas-Vega C, Peralta-Romero J, Cruz M, Tapia-Conyer  
513 R. Influence of obesity, parental history of diabetes, and genes in type 2 diabetes: A  
514 case-control study. *Sci Rep*. 2019;9(1):2748.
- 515 6. Almgren P, Lehtovirta M, Isomaa B, Sarelin L, Taskinen MR, Lyssenko V, Tuomi T,  
516 Groop L; Botnia Study Group. Heritability and familiarity of type 2 diabetes and  
517 related quantitative traits in the Botnia Study. *Diabetologia*. 2011;54(11):2811-2819.
- 518 7. Jang HM, Hwang MY, Kim BJ, Kim YJ. Validation and genetic heritability estimation  
519 of known type 2 diabetes related variants in the Korean population. *Genomics Inform*.  
520 2021;19(4):e37.
- 521 8. Chi Y, Wang X, Jia J, Huang T. Smoking status and type 2 diabetes, and  
522 cardiovascular disease: A comprehensive analysis of shared genetic etiology and  
523 causal relationship. *Front Endocrinol (Lausanne)*. 2022;13:809445.
- 524 9. Fuchsberger C, Flannick J, Teslovich TM, Mahajan A, Agarwala V, Gaulton KJ, Ma  
525 C, Fontanillas P, Moutsianas L, McCarthy DJ, Rivas MA, Perry JRB, Sim X,  
526 Blackwell TW, Robertson NR, Rayner NW, Cingolani P, Locke AE, Tajes JF,  
527 Highland HM, Dupuis J, Chines PS, Lindgren CM, Hartl C, Jackson AU, Chen H,

528 Huyghe JR, van de Bunt M, Pearson RD, Kumar A, Müller-Nurasyid M, Grarup N,  
529 Stringham HM, Gamazon ER, Lee J, Chen Y, Scott RA, Below JE, Chen P, Huang J,  
530 Go MJ, Stitzel ML, Pasko D, Parker SCJ, Varga TV, Green T, Beer NL, Day-Williams  
531 AG, Ferreira T, Fingerlin T, Horikoshi M, Hu C, Huh I, Ikram MK, Kim BJ, Kim Y, Kim  
532 YJ, Kwon MS, Lee J, Lee S, Lin KH, Maxwell TJ, Nagai Y, Wang X, Welch RP, Yoon  
533 J, Zhang W, Barzilai N, Voight BF, Han BG, Jenkinson CP, Kuulasmaa T, Kuusisto J,  
534 Manning A, Ng MCY, Palmer ND, Balkau B, Stančáková A, Abboud HE, Boeing H,  
535 Giedraitis V, Prabhakaran D, Gottesman O, Scott J, Carey J, Kwan P, Grant G,  
536 Smith JD, Neale BM, Purcell S, Butterworth AS, Howson JMM, Lee HM, Lu Y, Kwak  
537 SH, Zhao W, Danesh J, Lam VKL, Park KS, Saleheen D, So WY, Tam CHT, Afzal U,  
538 Aguilar D, Arya R, Aung T, Chan E, Navarro C, Cheng CY, Palli D, Correa A, Curran  
539 JE, Rybin D, Farook VS, Fowler SP, Freedman BI, Griswold M, Hale DE, Hicks PJ,  
540 Khor CC, Kumar S, Lehne B, Thuillier D, Lim WY, Liu J, van der Schouw YT, Loh M,  
541 Musani SK, Puppala S, Scott WR, Yengo L, Tan ST, Taylor HA Jr, Thameem F,  
542 Wilson G Sr, Wong TY, Njølstad PR, Levy JC, Mangino M, Bonnycastle LL,  
543 Schwarzmayr T, Fadista J, Surdulescu GL, Herder C, Groves CJ, Wieland T, Bork-  
544 Jensen J, Brandslund I, Christensen C, Koistinen HA, Doney ASF, Kinnunen L, Esko  
545 T, Farmer AJ, Hakaste L, Hodgkiss D, Kravic J, Lyssenko V, Hollensted M,  
546 Jørgensen ME, Jørgensen T, Ladenvall C, Justesen JM, Käräjämäki A, Kriebel J,  
547 Rathmann W, Lannfelt L, Lauritzen T, Narisu N, Linneberg A, Melander O, Milani L,  
548 Neville M, Orho-Melander M, Qi L, Qi Q, Roden M, Rolandsson O, Swift A,  
549 Rosengren AH, Stirrups K, Wood AR, Mihailov E, Blanche C, Carneiro MO, Maguire  
550 J, Poplin R, Shakir K, Fennell T, DePristo M, de Angelis MH, Deloukas P, Gjesing  
551 AP, Jun G, Nilsson P, Murphy J, Onofrio R, Thorand B, Hansen T, Meisinger C, Hu  
552 FB, Isomaa B, Karpe F, Liang L, Peters A, Huth C, O'Rahilly SP, Palmer CNA,  
553 Pedersen O, Rauramaa R, Tuomilehto J, Salomaa V, Watanabe RM, Syvänen AC,  
554 Bergman RN, Bharadwaj D, Bottinger EP, Cho YS, Chandak GR, Chan JCN, Chia  
555 KS, Daly MJ, Ebrahim SB, Langenberg C, Elliott P, Jablonski KA, Lehman DM, Jia

556 W, Ma RCW, Pollin TI, Sandhu M, Tandon N, Froguel P, Barroso I, Teo YY, Zeggini  
557 E, Loos RJJ, Small KS, Ried JS, DeFronzo RA, Grallert H, Glaser B, Metspalu A,  
558 Wareham NJ, Walker M, Banks E, Gieger C, Ingelsson E, Im HK, Illig T, Franks PW,  
559 Buck G, Trakalo J, Buck D, Prokopenko I, Mägi R, Lind L, Farjoun Y, Owen KR,  
560 Gloyn AL, Strauch K, Tuomi T, Kooner JS, Lee JY, Park T, Donnelly P, Morris AD,  
561 Hattersley AT, Bowden DW, Collins FS, Atzmon G, Chambers JC, Spector TD,  
562 Laakso M, Strom TM, Bell GI, Blangero J, Duggirala R, Tai ES, McVean G, Hanis  
563 CL, Wilson JG, Seielstad M, Frayling TM, Meigs JB, Cox NJ, Sladek R, Lander ES,  
564 Gabriel S, Burt NP, Mohlke KL, Meitinger T, Groop L, Abecasis G, Florez JC, Scott  
565 LJ, Morris AP, Kang HM, Boehnke M, Altshuler D, McCarthy MI. The genetic  
566 architecture of type 2 diabetes. *Nature*. 2016;536(7614):41-47.

567 10. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI,  
568 Ramos EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AE, Kong A, Kruglyak L,  
569 Mardis E, Rotimi CN, Slatkin M, Valle D, Whittemore AS, Boehnke M, Clark AG,  
570 Eichler EE, Gibson G, Haines JL, Mackay TF, McCarroll SA, Visscher PM. Finding  
571 the missing heritability of complex diseases. *Nature*. 2009;461(7265):747-753.

572 11. Wang L, Lee S, Gim J, Qiao D, Cho M, Elston RC, Silverman EK, Won S. Family-  
573 based rare variant association analysis: A fast and efficient method of multivariate  
574 phenotype association analysis. *Genet Epidemiol*. 2016;40(6):502-511.

575 12. Ma Y, Zhou Z, Li X, Yan Z, Ding K, Xiao H, Wu Y, Wu T, Chen D. Integrative  
576 identification of genetic loci jointly influencing diabetes-related traits and sleep traits  
577 of insomnia, sleep duration, and chronotypes. *Biomedicines*. 2022;10(2):368.

578 13. Mahajan A, Taliun D, Thurner M, Robertson NR, Torres JM, Rayner NW, Payne AJ,  
579 Steinthorsdottir V, Scott RA, Grarup N, Cook JP, Schmidt EM, Wuttke M, Sarnowski  
580 C, Mägi R, Nano J, Gieger C, Trompet S, Lecoeur C, Preuss MH, Prins BP, Guo X,  
581 Bielak LF, Below JE, Bowden DW, Chambers JC, Kim YJ, Ng MCY, Petty LE, Sim X,  
582 Zhang W, Bennett AJ, Bork-Jensen J, Brummert CM, Canouil M, Ec Kardt KU,  
583 Fischer K, Kardia SLR, Kronenberg F, Läll K, Liu CT, Locke AE, Luan J, Ntalla I,

584 Nylander V, Schönherr S, Schurmann C, Yengo L, Bottinger EP, Brandslund I,  
585 Christensen C, Dedoussis G, Florez JC, Ford I, Franco OH, Frayling TM, Giedraitis  
586 V, Hackinger S, Hattersley AT, Herder C, Ikram MA, Ingelsson M, Jørgensen ME,  
587 Jørgensen T, Kriebel J, Kuusisto J, Ligthart S, Lindgren CM, Linneberg A, Lyssenko  
588 V, Mamakou V, Meitinger T, Mohlke KL, Morris AD, Nadkarni G, Pankow JS, Peters  
589 A, Sattar N, Stančáková A, Strauch K, Taylor KD, Thorand B, Thorleifsson G,  
590 Thorsteinsdottir U, Tuomilehto J, Witte DR, Dupuis J, Peyser PA, Zeggini E, Loos  
591 RJF, Froguel P, Ingelsson E, Lind L, Groop L, Laakso M, Collins FS, Jukema JW,  
592 Palmer CNA, Grallert H, Metspalu A, Dehghan A, Köttgen A, Abecasis GR, Meigs  
593 JB, Rotter JI, Marchini J, Pedersen O, Hansen T, Langenberg C, Wareham NJ,  
594 Stefansson K, Gloyn AL, Morris AP, Boehnke M, McCarthy MI. Fine-mapping type 2  
595 diabetes loci to single-variant resolution using high-density imputation and islet-  
596 specific epigenome maps. *Nat Genet.* 2018;50(11):1505-1513.

597 14. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M,  
598 Pirruccello JP, Ripatti S, Chasman DI, Willer CJ, Johansen CT, Fouchier SW, Isaacs  
599 A, Peloso GM, Barbalic M, Ricketts SL, Bis JC, Aulchenko YS, Thorleifsson G,  
600 Feitosa MF, Chambers J, Orho-Melander M, Melander O, Johnson T, Li X, Guo X, Li  
601 M, Shin Cho Y, Jin Go M, Jin Kim Y, Lee JY, Park T, Kim K, Sim X, Twee-Hee Ong  
602 R, Croteau-Chonka DC, Lange LA, Smith JD, Song K, Hua Zhao J, Yuan X, Luan J,  
603 Lamina C, Ziegler A, Zhang W, Zee RY, Wright AF, Witteman JC, Wilson JF,  
604 Willemsen G, Wichmann HE, Whitfield JB, Waterworth DM, Wareham NJ, Waeber G,  
605 Vollenweider P, Voight BF, Vitart V, Uitterlinden AG, Uda M, Tuomilehto J,  
606 Thompson JR, Tanaka T, Surakka I, Stringham HM, Spector TD, Soranzo N, Smit  
607 JH, Sinisalo J, Silander K, Sijbrands EJ, Scuteri A, Scott J, Schlessinger D, Sanna S,  
608 Salomaa V, Saharinen J, Sabatti C, Ruukonen A, Rudan I, Rose LM, Roberts R,  
609 Rieder M, Psaty BM, Pramstaller PP, Pichler I, Perola M, Penninx BW, Pedersen NL,  
610 Pattaro C, Parker AN, Pare G, Oostra BA, O'Donnell CJ, Nieminen MS, Nickerson  
611 DA, Montgomery GW, Meitinger T, McPherson R, McCarthy MI, McArdle W, Masson



612 D, Martin NG, Marroni F, Mangino M, Magnusson PK, Lucas G, Luben R, Loos RJ,  
613 Lokki ML, Lettre G, Langenberg C, Launer LJ, Lakatta EG, Laaksonen R, Kyvik KO,  
614 Kronenberg F, König IR, Khaw KT, Kaprio J, Kaplan LM, Johansson A, Jarvelin MR,  
615 Janssens AC, Ingelsson E, Igl W, Kees Hovingh G, Hottenga JJ, Hofman A, Hicks  
616 AA, Hengstenberg C, Heid IM, Hayward C, Havulinna AS, Hastie ND, Harris TB,  
617 Haritunians T, Hall AS, Gyllensten U, Guiducci C, Groop LC, Gonzalez E, Gieger C,  
618 Freimer NB, Ferrucci L, Erdmann J, Elliott P, Ejebe KG, Döring A, Dominiczak AF,  
619 Demissie S, Deloukas P, de Geus EJ, de Faire U, Crawford G, Collins FS, Chen YD,  
620 Caulfield MJ, Campbell H, Burt NP, Bonnycastle LL, Boomsma DI, Boekholdt SM,  
621 Bergman RN, Barroso I, Bandinelli S, Ballantyne CM, Assimes TL, Quertermous T,  
622 Altshuler D, Seielstad M, Wong TY, Tai ES, Feranil AB, Kuzawa CW, Adair LS,  
623 Taylor HA Jr, Borecki IB, Gabriel SB, Wilson JG, Holm H, Thorsteinsdottir U,  
624 Gudnason V, Krauss RM, Mohlke KL, Ordovas JM, Munroe PB, Kooner JS, Tall AR,  
625 Hegele RA, Kastelein JJ, Schadt EE, Rotter JI, Boerwinkle E, Strachan DP, Mooser  
626 V, Stefansson K, Reilly MP, Samani NJ, Schunkert H, Cupples LA, Sandhu MS,  
627 Ridker PM, Rader DJ, van Duijn CM, Peltonen L, Abecasis GR, Boehnke M,  
628 Kathiresan S. Biological, clinical and population relevance of 95 loci for blood lipids.  
629 *Nature*. 2010;466(7307):707-713.

630 15. Piko P, Werissa NA, Fiatal S, Sandor J, Adany R. Impact of genetic factors on the  
631 age of onset for type 2 diabetes mellitus in addition to the conventional risk factors. *J*  
632 *Pers Med*. 2020;11(1):6.

633 16. Humphries SE, Gable D, Cooper JA, Ireland H, Stephens JW, Hurel SJ, Li KW,  
634 Palmen J, Miller MA, Cappuccio FP, Elkeles R, Godsland I, Miller GJ, Talmud PJ.  
635 Common variants in the TCF7L2 gene and predisposition to type 2 diabetes in UK  
636 European Whites, Indian Asians and Afro-Caribbean men and women. *J Mol Med*  
637 *(Berl)*. 2006;84(12)1005-1014.

- 638 17. Kautzky-Willer A, Harreiter J, Pacini G. Sex and gender differences in risk,  
639 pathophysiology and complications of type 2 diabetes mellitus. *Endocr Rev.*  
640 2016;37(3):278-316.
- 641 18. SIGMA Type 2 Diabetes Consortium, Williams AL, Jacobs SB, Moreno-Macías H,  
642 Huerta-Chagoya A, Churchhouse C, Márquez-Luna C, García-Ortíz H, Gómez-  
643 Vázquez MJ, Burt NP, Aguilar-Salinas CA, González-Villalpando C, Florez JC,  
644 Orozco L, Haiman CA, Tusié-Luna T, Altshuler D. Sequence variants in SLC16A11  
645 are a common risk factor for type 2 diabetes in Mexico. *Nature.* 2014;506(7486)97-  
646 101.
- 647 19. Mercader JM, Florez JC. The genetic basis of type 2 diabetes in Hispanics and Latin  
648 Americans: Challenges and opportunities. *Front Public Health.* 2017;5:329.
- 649 20. SIGMA Type 2 Diabetes Consortium, Estrada K, Aukrust I, Bjørkhaug L, Burt NP,  
650 Mercader JM, García-Ortiz H, Huerta-Chagoya A, Moreno-Macías H, Walford G,  
651 Flannick J, Williams AL, Gómez-Vázquez MJ, Fernandez-Lopez JC, Martínez-  
652 Hernández A, Jiménez-Morales S, Centeno-Cruz F, Mendoza-Caamal E, Revilla-  
653 Monsalve C, Islas-Andrade S, Córdova EJ, Soberón X, González-Villalpando ME,  
654 Henderson E, Wilkens LR, Le Marchand L, Arellano-Campos O, Ordóñez-Sánchez  
655 ML, Rodríguez-Torres M, Rodríguez-Guillén R, Riba L, Najmi LA, Jacobs SB, Fennell  
656 T, Gabriel S, Fontanillas P, Hanis CL, Lehman DM, Jenkinson CP, Abboud HE, Bell  
657 GI, Cortes ML, Boehnke M, González-Villalpando C, Orozco L, Haiman CA, Tusié-  
658 Luna T, Aguilar-Salinas CA, Altshuler D, Njølstad PR, Florez JC, MacArthur DG.  
659 Association of a low-frequency variant in HNF1A with type 2 diabetes in a Latino  
660 population. *JAMA.* 2014;311(22):2305-2314.
- 661 21. Mercader JM, Liao RG, Bell AD, Dymek Z, Estrada K, Tukiainen T, Huerta-Chagoya  
662 A, Moreno-Macías H, Jablonski KA, Hanson RL, Walford GA, Moran I, Chen L,  
663 Agarwala V, Ordoñez-Sánchez ML, Rodríguez-Guillen R, Rodríguez-Torres M,  
664 Segura-Kato Y, García-Ortiz H, Centeno-Cruz F, Barajas-Olmos F, Caulkins L,  
665 Puppala S, Fontanillas P, Williams AL, Bonàs-Guarch S, Hartl C, Ripke S; Diabetes

666 Prevention Program Research Group, Tooley K, Lane J, Zerrweck C, Martínez-  
667 Hernández A, Córdova EJ, Mendoza-Caamal E, Contreras-Cubas C, González-  
668 Villalpando ME, Cruz-Bautista I, Muñoz-Hernández L, Gómez-Velasco D, Alvirde U,  
669 Henderson BE, Wilkens LR, Le Marchand L, Arellano-Campos O, Riba L, Harden M;  
670 Broad Genomics Platform, Gabriel S; T2D-GENES Consortium, Abboud HE, Cortes  
671 ML, Revilla-Monsalve C, Islas-Andrade S, Soberon X, Curran JE, Jenkinson CP,  
672 DeFronzo RA, Lehman DM, Hanis CL, Bell GI, Boehnke M, Blangero J, Duggirala R,  
673 Saxena R, MacArthur D, Ferrer J, McCarroll SA, Torrents D, Knowler WC, Baier LJ,  
674 Burt N, González-Villalpando C, Haiman CA, Aguilar-Salinas CA, Tusié-Luna T,  
675 Flannick J, Jacobs SBR, Orozco L, Altshuler D, Florez JC; SIGMA T2D Genetics  
676 Consortium. A loss-of-function splice acceptor variant in IGF2 is protective for type 2  
677 diabetes. *Diabetes*. 2017;66(11): 2903-2914.

678 22. American Diabetes Association. Standards of Medical Care in Diabetes-2022  
679 Abridged for Primary Care Providers. *Clin Diabetes*. 2022;40(1):10-38.

680 23. Babyak MA. What you see may not be what you get: a brief, nontechnical  
681 introduction to overfitting in regression-type models. *Psychosom Med*.  
682 2004;66(3):411-421.

683 24. Nagelkerke NJD. A note on a general definition of the coefficient of determination.  
684 *Biometrika*. 1991;78(3):691-692.

685 25. Faul F, Erdfelder E, Lang AG, Buchner A. G\*Power 3: a flexible statistical power  
686 analysis program for the social, behavioral, and biomedical sciences. *Behav Res*  
687 *Methods*. 2007;39(2):175-191.

688 26. Kong A, Steinthorsdottir V, Masson G, Thorleifsson G, Sulem P, Besenbacher S,  
689 Jonasdottir A, Sigurdsson A, Kristinsson KT, Jonasdottir A, Frigge ML, Gylfason A,  
690 Olason PI, Gudjonsson SA, Sverrisson S, Stacey SN, Sigurgeirsson B,  
691 Benediktsdottir KR, Sigurdsson H, Jonsson T, Benediktsson R, Olafsson JH,  
692 Johannsson OT, Hreidarsson AB, Sigurdsson G; DIAGRAM Consortium, Ferguson-  
693 Smith AC, Gudbjartsson DF, Thorsteinsdottir U, Stefansson K. Parental origin of

- 694 sequence variants associated with complex diseases. *Nature*. 2009;462(7275):868-  
695 874.
- 696 27. Ding M, Ahmad S, Qi L, Hu Y, Bhupathiraju SN, Guasch-Ferré M, Jensen MK,  
697 Chavarro JE, Ridker PM, Willett WC, Chasman DI, Hu FB, Kraft P. Additive and  
698 multiplicative interactions between genetic risk score and family history and lifestyle  
699 in relation to risk of type 2 diabetes. *Am J Epidemiol*. 2020;189(5):445-460.
- 700 28. Amuta AO, Mkuu R, Jacobs W, Barry AE. Number and severity of type 2 diabetes  
701 among family members are associated with nutrition and physical activity behaviors.  
702 *Front Public Health*. 2017;5:157.
- 703 29. InterAct Consortium, Scott RA, Langenberg C, Sharp SJ, Franks PW, Rolandsson O,  
704 Drogan D, van der Schouw YT, Ekelund U, Kerrison ND, Ardanaz E, Arriola L,  
705 Balkau B, Barricarte A, Barroso I, Bendinelli B, Beulens JW, Boeing H, de Lauzon-  
706 Guillain B, Deloukas P, Fagherazzi G, Gonzalez C, Griffin SJ, Groop LC, Halkjaer J,  
707 Huerta JM, Kaaks R, Khaw KT, Krogh V, Nilsson PM, Norat T, Overvad K, Panico S,  
708 Rodriguez-Suarez L, Romaguera D, Romieu I, Sacerdote C, Sánchez MJ,  
709 Spijkerman AM, Teucher B, Tjønneland A, Tumino R, van der A DL, Wark PA,  
710 McCarthy MI, Riboli E, Wareham NJ. The link between family history and risk of type  
711 2 diabetes is not explained by anthropometric, lifestyle or genetic risk factors: the  
712 EPIC-InterAct study. *Diabetologia*. 2013;56(1):60-69.
- 713 30. Watts EL, Appleby PN, Albanes D, Black A, Chan JM, Chen C, Cirillo PM, Cohn BA,  
714 Cook MB, Donovan JL, Ferrucci L, Garland CF, Giles GG, Goodman PJ, Habel LA,  
715 Haiman CA, Holly JMP, Hoover RN, Kaaks R, Knekt P, Kolonel LN, Kubo T, Le  
716 Marchand L, Luostarinen T, MacInnis RJ, Mäenpää HO, Männistö S, Metter EJ,  
717 Milne RL, Nomura AMY, Oliver SE, Parsons JK, Peeters PH, Platz EA, Riboli E,  
718 Ricceri F, Rinaldi S, Rissanen H, Sawada N, Schaefer CA, Schenk JM, Stanczyk FZ,  
719 Stampfer M, Stattin P, Stenman UH, Tjønneland A, Trichopoulou A, Thompson IM,  
720 Tsugane S, Vatten L, Whittemore AS, Ziegler RG, Allen NE, Key TJ, Travis RC.  
721 Circulating sex hormones in relation to anthropometric, sociodemographic and

- 722 behavioural factors in an international dataset of 12,300 men. *PLoS One*.  
723 2017;12(12): e0187741.
- 724 31. Benz V, Kintscher U, Foryst-Ludwig A. Sex-specific differences in Type 2 Diabetes  
725 Mellitus and dyslipidemia therapy: PPAR agonists. *Handb Exp Pharmacol*.  
726 2012;(214):387-410.
- 727 32. Zhang H, Sairam, MR. Sex hormone imbalances and adipose tissue dysfunction  
728 impacting on metabolic syndrome; a paradigm for the discovery of novel adipokines.  
729 *Horm Mol Biol Clin Investig*. 2014;17(2):89-97.
- 730 33. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes:  
731 estimates for the year 2000 and projections for 2030. *Diabetes Care*.  
732 2004;27(5):1047-1053.
- 733 34. Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology  
734 of type 2 diabetes - Global burden of disease and forecasted trends. *J Epidemiol  
735 Glob Health*. 2020;10(1):107-111.
- 736 35. International Diabetes Federation. IDF Diabetes Atlas 2021: IDF Atlas. 10th Edition.  
737 Available from: <https://diabetesatlas.org/atlas/tenth-edition/>.
- 738 36. Wändell PE, Carlsson AC. Gender differences and time trends in incidence and  
739 prevalence of type 2 diabetes in Sweden--a model explaining the diabetes epidemic  
740 worldwide today? *Diabetes Res Clin Pract*. 2014;106(3):e90-92.
- 741 37. Institute for Health Metrics and Evaluation. GBD 2019. Available from:  
742 <http://ihmeuw.org/5pb2>.
- 743 38. Fappi A, Mittendorfer B. Different physiological mechanisms underlie an adverse  
744 cardiovascular disease risk profile in men and women. *Proc Nutr Soc*.  
745 2020;79(2):210-218.
- 746 39. Kanaya AM, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V, Cauley JA,  
747 Barrett-Connor E; Heart and Estrogen/progestin Replacement Study. Glycemic  
748 effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin

- 749 Replacement Study. A randomized, double-blind, placebo-controlled trial. *Ann Intern*  
750 *Med.* 2003;138(1):1-9.
- 751 40. Brand JS, van der Schouw YT, Onland-Moret NC, Sharp SJ, Ong KK, Khaw KT,  
752 Ardanaz E, Amiano P, Boeing H, Chirlaque MD, Clavel-Chapelon F, Crowe FL, de  
753 Lauzon-Guillain B, Duell EJ, Fagherazzi G, Franks PW, Gioni S, Groop LC, Kaaks  
754 R, Key TJ, Nilsson PM, Overvad K, Palli D, Panico S, Quirós JR, Rolandsson O,  
755 Sacerdote C, Sánchez MJ, Slimani N, Teucher B, Tjønneland A, Tumino R, van der  
756 A DL, Feskens EJ, Langenberg C, Forouhi NG, Riboli E, Wareham NJ; InterAct  
757 Consortium. Age at menopause, reproductive life span, and type 2 diabetes risk:  
758 results from the EPIC-InterAct study. *Diabetes Care.* 2013;36(4):1012-1019.
- 759 41. Anderwald C, Gastaldelli A, Tura A, Krebs M, Promintzer-Schifferl M, Kautzky-Willer  
760 A, Stadler M, DeFronzo RA, Pacini G, Bischof MG. Mechanism and effects of  
761 glucose absorption during an oral glucose tolerance test among females and males.  
762 *J Clin Endocrinol Metab.* 2011;96(2):515-524.
- 763 42. Díaz A, López-Grueso R, Gambini J, Monleón D, Mas-Bargues C, Abdelaziz KM,  
764 Viña J, Borrás C. Sex differences in age-associated type 2 diabetes in rats-Role of  
765 estrogens and oxidative stress. *Oxid Med Cell Longev.* 2019;2019: 6734836.
- 766 43. Bian C, Bai B, Gao Q, Li S, Zhao Y. 17beta-estradiol regulates glucose metabolism  
767 and insulin secretion in rat islet beta cells through GPER and Akt/mTOR/GLUT2  
768 pathway. *Front Endocrinol (Lausanne).* 2019;10:531.
- 769 44. Fui MN, Dupuis P, Grossmann M. Lowered testosterone in male obesity:  
770 mechanisms, morbidity and management. *Asian J Androl.* 2014;16(2):223-231.
- 771 45. Wittert G, Bracken K, Robledo KP, Grossmann M, Yeap BB, Handelsman DJ,  
772 Stuckey B, Conway A, Inder W, McLachlan R, Allan C, Jesudason D, Fui MNT,  
773 Hague W, Jenkins A, Daniel M, Gebiski V, Keech A. Testosterone treatment to  
774 prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a  
775 randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. *Lancet Diabetes*  
776 *Endocrinol.* 2021;9(1):32-45.

- 777 46. Yokomizo H, Inoguchi T, Sonoda N, Sakaki Y, Maeda Y, Inoue T, Hirata E, Takei R,  
778 Ikeda N, Fujii M, Fukuda K, Sasaki H, Takayanagi R. Maternal high-fat diet induces  
779 insulin resistance and deterioration of pancreatic beta-cell function in adult offspring  
780 with sex differences in mice. *Am J Physiol Endocrinol Metab.* 2014;306(10):E1163-  
781 1175.
- 782 47. Meigs JB, Cupples LA, Wilson PW. Parental transmission of type 2 diabetes: the  
783 Framingham Offspring Study. *Diabetes.* 2000;49(12):2201-2207.
- 784 48. Travers ME, Mackay DJ, Dekker Nitert M, Morris AP, Lindgren CM, Berry A, Johnson  
785 PR, Hanley N, Groop LC, McCarthy MI, Gloyn AL. Insights into the molecular  
786 mechanism for type 2 diabetes susceptibility at the KCNQ1 locus from temporal  
787 changes in imprinting status in human islets. *Diabetes.* 2013;62(3):987-992.
- 788 49. Thakur N, Tiwari VK, Thomassin H, Pandey RR, Kanduri M, Göndör A, Grange T,  
789 Ohlsson R, Kanduri C. An antisense RNA regulates the bidirectional silencing  
790 property of the Kcnq1 imprinting control region. *Mol Cell Biol.* 2004;24(18):7855-  
791 7862.

792 **Figure legends**

793 **Figure 1.** Graphic representation of the chromosome 11p15.5 region.

794

795 **Figure 2.** Influence ( $R^2$ ) of genes and parental history of T2D on T2D development.

796 MLR analysis stratified by age at T2D diagnosis and sex was conducted to demonstrate (A)  
797 the effect of groups of genes, (B) parental history, and (C) both factors on T2D development  
798 (early diagnosis was  $\leq 45$  years whereas late diagnosis was  $\geq 46$  years). Gene groups and  
799 parental history as factors were introduced into the models as successive blocks. The gene  
800 groups were as follows: Group 1, five SNPs located in genes on chromosome region  
801 11p15.5 that are involved in insulin production (*INS*, *IGF2*, and *KCNQ1*); Group 2, seven  
802 SNPs located in genes outside of chromosome 11 and involved in insulin production; Group  
803 3, six SNPs located in genes involved in peripheral insulin resistance; Group 4, five SNPs  
804 located in genes involved in inflammation and other functions. The influence of parental  
805 history of T2D was investigated according to having a mother with T2D, a father with T2D, or  
806 both parents with T2D. In panel C, the effects of genes and parental history were  
807 investigated with genes as the first block and parental history as the second block and vice  
808 versa.

809 Abbreviations: MLR, multivariate logistic regression; SNP, single nucleotide polymorphism;  
810 T2D, type 2 diabetes.

811

812 **Figure 3.** Analysis of allelic frequency stratified by type of parental history of T2D in males  
813 diagnosed early. A comparison of frequencies of risk and alternative alleles for SNPs in  
814 genes located in the chromosome region 11p15.5 (*INS* and *KCNQ1*) and *TCF7L2* between  
815 cases and controls stratified by the type of parental history of T2D (mother only, father only,  
816 both parents). *P* values were calculated using a chi-square test.

817 Abbreviations: SNP, single nuclear polymorphism; T2D, type 2 diabetes.

818



819 **Figure 4.** Influence ( $R^2$ ) of genes, parental history of T2D, BMI, and WHR on T2D  
820 development. (A) MLR analysis was conducted to determine the involvement of BMI and  
821 WHR in the four models of T2D (stratified by age of T2D diagnosis and sex). (B) MLR  
822 analysis of the participation of parental history, genes, and adjusted BMI in the four models.  
823 Abbreviations: BMI, body mass index; MLR, multivariate logistic regression; T2D, type 2  
824 diabetes; WHR, waist-hip ratio.

825

826 **Figure 5.** Influence ( $R^2$ ) of obesity and fat distribution and genes and parental history on  
827 T2D development overlap. Overlapping analysis was performed with stratification by age of  
828 T2D diagnosis and sex. Overlapping analysis of (A) BMI with genes, (B) BMI with parental  
829 history, (C) WHR with genes, and (D) WHR with parental history are shown. The overlapping  
830 effect of  $R^2$  between genes and BMI and between parental history and BMI was observed by  
831 introducing BMI as the first block and either genes or parental history as the second block  
832 and then conducting the analysis with the blocks reversed.

833 Abbreviations: BMI, body mass index; PH, parental history; T2D, type 2 diabetes; WHR,  
834 weight distribution.

835

836 **Figure 6.** Correlation analysis between the number of risk alleles in *KCNQ1* in relation to  
837 obesity and fat distribution. (A) Correlation between the number of risk alleles in *KCNQ1* and  
838 BMI in males and females with a T2D diagnosis  $\leq 45$  years and  $\geq 46$  years of age. (B)  
839 Correlation between the number of risk alleles in *KCNQ1* and WHR in males and females  
840 with a T2D diagnosis  $\leq 45$  years and  $\geq 46$  years of age. Correlations and *P* values were  
841 calculated using the Pearson correlation test.

842 Abbreviations: BMI, body mass index; T2D, type 2 diabetes; WHR, weight distribution.

843 **Tables**844 **Table 1. Association of 23 SNPs with type 2 diabetes among the whole sample (N = 4040 chromosomes)**

Locus (SNP)	Chr	Position	RA	AA	MAF	ULR			
						OR (95% CI)	p-Wald	R <sup>2</sup>	SI
<b>Group 1</b>									
<i>INS-IGF2</i> (rs149483638)	11	2140300	C	T <sup>a</sup>	0.281	1.25 (1.1–1.4)	0.0022	0.003	>0.05
<i>INS</i> (rs689)	11	2160994	A <sup>a</sup>	T	0.188	1.32 (1.1–1.5)	0.0005	0.004	0.06
<i>KCNQ1</i> (rs2237897)	11	2837316	C	T <sup>a</sup>	0.392	1.44 (1.3–1.6)	< 0.0001	0.010	>0.05
<i>KCNQ1</i> (rs163168)	11	2803115	C	T <sup>a</sup>	0.436	1.39 (1.2–1.6)	< 0.0001	0.008	>0.05
<i>SLC22A18</i> (rs450208)	11	2910751	T	G <sup>a</sup>	0.311	1.38 (1.2–1.6)	< 0.0001	0.007	>0.05
<b>Group 2</b>									
<i>IGF2BP2</i> (rs4402960)	3	185793899	T <sup>a</sup>	G	0.163	1.28 (1.1–1.5)	0.0031	0.003	0.07
<i>TCF7L2</i> (rs7903146)	10	112998590	T <sup>a</sup>	C	0.121	1.5 (1.3–1.8)	< 0.0001	0.007	>0.05
<i>CDKN2A</i> (rs10811661)	9	22134095	T	C <sup>a</sup>	0.096	1.12 (0.9–1.4)	0.029	0	>0.05
<i>SLC30A8</i> (rs3802177)	8	117172786	A <sup>a</sup>	G	0.272	1.15 (1–1.3)	0.044	0.001	>0.05
<i>HNF1A</i> (rs483353044)	12	120999288	A <sup>a</sup>	G	0.003	2 (0.8–5)	0.13	0.001	>0.05
<i>WFS1</i> (rs4458523)	4	6288259	G	T <sup>a</sup>	0.233	1.07 (0.9–1.2)	0.35	0	>0.05
<i>HMG20A</i> (rs1005752)	15	77525786	C <sup>a</sup>	A	0.419	0.94 (0.8–1.1)	0.34	0	>0.05

**Group 3**

<i>SLC16A11</i> (rs75493593)	17	7041768	T <sup>a</sup>	G	0.374	1.31 (1.2–1.5)	<0.0001	0.006	>0.05
<i>IRS1</i> (rs1801278)	2	226795828	T <sup>a</sup>	C	0.027	0.98 (0.7–1.4)	0.91	0	>0.05
<i>FABP2</i> (rs1799883)	4	119320747	T <sup>a</sup>	C	0.241	0.99 (0.9–1.1)	0.89	0	>0.05
<i>CAPN10</i> (rs7607759)	2	240596709	G <sup>a</sup>	A	0.053	1.04 (0.8–1.4)	0.76	0	>0.05
<i>PPP1R3A</i> (rs1799999)	7	113878379	A <sup>a</sup>	C	0.291	1.09 (0.9–1.2)	0.23	0	>0.05
<i>PTPRD</i> (rs10511567)	9	11606348	C <sup>a</sup>	T	0.278	1.02 (0.9–1.2)	0.76	0	>0.05

**Group 4**

<i>IL6</i> (rs1800795)	7	22727026	C <sup>a</sup>	G	0.079	1.01 (0.8–1.3)	0.93	0	>0.05
<i>NOS3</i> (rs2070744)	7	150992991	C <sup>a</sup>	T	0.145	0.84 (0.7–1)	0.054	0.001	>0.05
<i>CPED1</i> (rs10261386)	7	120711855	C <sup>a</sup>	T	0.347	1.04 (0.9–1.2)	0.55	0	>0.05
<i>KHDRBS3</i> (rs6577691)	8	135961229	G <sup>a</sup>	T	0.123	0.84 (0.7–1)	0.076	0.001	>0.05
<i>CACNA1H</i> (rs4984636)	16	1202441	C <sup>a</sup>	T	0.113	0.83 (0.7–1)	0.073	0.001	>0.05

**No. genes**

12

**Sum of univariate R<sup>2</sup>**

0.053

845 Abbreviations: AA, alternative allele; Chr, chromosome; CI, confidence interval; MAF, major allele frequency; OR, odds ratio; R<sup>2</sup>,  
846 variability of T2D explained by the SNP; RA, risk allele; SI, sex interaction; SNP, single nucleotide polymorphism; ULR, univariate  
847 logistic regression.  
848 <sup>a</sup>Minor allele.

- 849 Group 1, insulin production located in the chromosome region 11p15.5 ; Group 2, insulin production located in other chromosomes ;
- 850 Group 3, peripheral insulin resistance; Group 4, inflammation and other functions

851 **Table 2. Allele association of 23 SNPs with type 2 diabetes stratified by age of type 2 diabetes diagnosis and sex among the**  
 852 **total population (N = 4040 chromosomes).**

Locus (SNP)	ULR							
	T2D diagnosis ≤45 years				T2D diagnosis ≥46 years			
	Females		Males		Females		Males	
	OR (95% CI)	p-Wald	OR (95% CI)	p-Wald	OR (95% CI)	p-Wald	OR (95% CI)	p-Wald
<b>Group 1</b>								
<i>INS-IGF2</i> (rs149483638)	1.06 (0.8–1.3)	0.61	1.38 (1.1–1.8) <sup>a</sup>	0.014	1.1 (0.9–1.4)	0.44	1.56 (1.2–2) <sup>a</sup>	0.0010
<i>INS</i> (rs689)	1.09 (0.8–1.4)	0.52	1.63 (1.2–2.1) <sup>a</sup>	0.0003	1.23 (1–1.6) <sup>a</sup>	0.11	1.43 (1.1–1.9) <sup>a</sup>	0.012
<i>KCNQ1</i> (rs2237897)	1.31 (1.1–1.6)	0.016	1.97 (1.5–2.5) <sup>a</sup>	< 0.0001	1.09 (0.9–1.4)	0.46	1.56 (1.2–2) <sup>a</sup>	0.0002
<i>CDKN1C</i> (rs163168)	1.36 (1.1–1.7) <sup>a</sup>	0.0043	1.82 (1.4–2.3) <sup>a</sup>	< 0.0001	1.05 (0.8–1.3)	0.64	1.45 (1.2–1.8) <sup>a</sup>	0.0015
<i>SLC22A18</i> (rs450208)	1.46 (1.2–1.9) <sup>a</sup>	0.0014	1.27 (1–1.6)	0.053	1.38 (1.1–1.8) <sup>a</sup>	0.0092	1.36 (1.1–1.8)	0.015
<b>Group 2</b>								
<i>IGF2BP2</i>	1.16 (0.9–1.5)	0.26	1.65 (1.2–2.2) <sup>a</sup>	0.0007	1.09 (0.8–1.4)	0.54	1.37 (1–1.9)	0.042

(rs4402960)

*TCF7L2*

1.22 (0.9–1.6)<sup>a</sup> 0.15 2.21 (1.6–3)<sup>a</sup> < 0.0001 1.15 (0.9–1.5) 0.34 1.83 (1.3–2.5)<sup>a</sup> 0.0003

(rs7903146)

*CDKN2A*

1.47 (1–2.2)<sup>a</sup> 0.049 0.92 (0.6–1.3) 0.65 1.07 (0.7–1.5) 0.73 1.08 (0.7–1.6) 0.72

(rs10811661)

*SLC30A8*

1.31 (1–1.6)<sup>a</sup> 0.018 1.43 (1.1–1.8)<sup>a</sup> 0.0034 0.95 (0.7–1.2) 0.65 0.96 (0.7–1.2) 0.77

(rs3802177)

*HNF1A*

1.92 (0.4–9.5) 0.43 1.97 (0.5–7.9) 0.34 2.85 (0.6–12.8)<sup>a</sup> 0.17 1.53 (0.3–6.9) 0.58

(rs483353044)

*WFS1*

1.08 (0.8–1.4) 0.52 1.3 (1–1.7)<sup>a</sup> 0.065 0.99 (0.8–1.3) 0.95 0.99 (0.8–1.3) 0.94

(rs4458523)

*HMG20A*

0.97 (0.8–1.2) 0.81 1.04 (0.8–1.3) 0.73 0.87 (0.7–1.1)<sup>a</sup> 0.19 0.88 (0.7–1.1)<sup>a</sup> 0.27

(rs1005752)

**Group 3**

*SLC16A11*

1.51 (1.2–1.9)<sup>a</sup> < 0.0001 1.34 (1.1–1.7)<sup>a</sup> 0.011 1.24 (1–1.5)<sup>a</sup> 0.048 1.14 (0.9–1.4)<sup>a</sup> 0.27

(rs75493593)

*IRS1* (rs1801278)

0.58 (0.3–1.2) 0.14 0.94 (0.5–1.9) 0.87 1.21 (0.7–2.2) 0.53 1.35 (0.7–2.6) 0.38

*FABP2*

0.89 (0.7–1.1) 0.34 1.23 (1–1.6) 0.11 0.93 (0.7–1.2) 0.57 0.93 (0.7–1.2) 0.60

(rs1799883)

<i>CAPN10</i> (rs7607759)	0.76 (0.5–1.2) <sup>a</sup>	0.23	1.06 (0.6–1.8)	0.83	1.17 (0.8–1.8)	0.46	1.26 (0.8–2.1)	0.37
<i>PPP1R3A</i> (rs1799999)	1.36 (1.1–1.7) <sup>a</sup>	0.0061	0.83 (0.6–1.1)	0.14	1.25 (1–1.6) <sup>a</sup>	0.060	0.94 (0.7–1.2)	0.64
<i>PTPRD</i> (rs10511567)	1.28 (1–1.6) <sup>a</sup>	0.029	0.76 (0.6–1) <sup>a</sup>	0.036	1.16 (0.9–1.5) <sup>a</sup>	0.22	0.9 (0.7–1.1)	0.39
<b>Group 4</b>								
<i>IL6</i> (rs1800795)	0.8 (0.5–1.2)	0.25	1.02 (0.7–1.6)	0.94	0.82 (0.6–1.2)	0.32	1.67 (1.1–2.5) <sup>a</sup>	0.0093
<i>NOS3</i> (rs2070744)	0.71 (0.5–1) <sup>a</sup>	0.028	0.86 (0.6–1.2) <sup>a</sup>	0.38	0.85 (0.6–1.1)	0.28	0.99 (0.7–1.4)	0.96
<i>CPED1</i> (rs10261386)	0.95 (0.8–1.2)	0.62	1.1 (0.9–1.4)	0.42	0.94 (0.8–1.2)	0.61	1.23 (1–1.5)	0.088
<i>KHDRBS3</i> (rs6577691)	0.9 (0.7–1.2)	0.52	0.73 (0.5–1) <sup>a</sup>	0.083	1.02 (0.7–1.4)	0.91	0.68 (0.5–1) <sup>a</sup>	0.046
<i>CACNA1H</i> (rs4984636)	0.89 (0.6–1.2)	0.49	0.97 (0.7–1.4)	0.86	0.54 (0.4–0.8) <sup>a</sup>	0.0022	0.97 (0.7–1.4)	0.87
<b>No. SNPs</b>	9		12		4		10	
<b>Sum of univariate R<sup>2</sup></b>	0.056		0.14		0.02		0.079	

853 Abbreviations: CI, confidence interval; OR, odds ratio;  $R^2$ , variability of T2D explained by these genes; SNP, single nucleotide polymorphism; ULR,  
854 univariate logistic regression.  
855 <sup>a</sup>Indicates SNPs that remain in the multivariate model.



# GRCh38 chromosome 11p15.5 (*IGF2-INS-TH-KCNQ1-SLC22A18*)




Figure 1




Figure 2A.

**B**




Figure 2B

C




Figure 2C




Figure 3



**A****B**

Figure 4

**A**




Figure 5A


**B**

Figure 5B




**C**

Figure 5C

D




Figure 5D

### Early T2D diagnosis

### Late T2D diagnosis




Figure 6